Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of MB07811 for 12 Weeks Followed by a 6-Week Off Drug Phase in Subjects With Primary Hypercholesterolemia.

Trial Profile

Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of MB07811 for 12 Weeks Followed by a 6-Week Off Drug Phase in Subjects With Primary Hypercholesterolemia.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2011

At a glance

  • Drugs VK 2809 (Primary)
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Sponsors Ligand Pharmaceuticals; Metabasis Therapeutics
  • Most Recent Events

    • 20 Oct 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 14 Apr 2009 Official Title added, primary endpoint identified as low density lipoprotein cholesterol level, clinical response rate, ClinicalTrial.gov reported planned initiation date as Apr 2009 as reported by ClinicalTrials.gov.
    • 14 Apr 2009 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top